Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China · Delayed Price · Currency is CNY 14.87
+0.12 (0.81%)
Apr 15, 2026, 10:05 AM CST
SHA:600161 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,149 | 6,013 | 5,162 | 4,244 | 4,112 |
Other Revenue | 19 | 19.11 | 18.38 | 16.86 | - |
| 6,168 | 6,032 | 5,180 | 4,261 | 4,112 | |
Revenue Growth (YoY) | 2.26% | 16.43% | 21.57% | 3.63% | 19.35% |
Cost of Revenue | 3,491 | 2,745 | 2,553 | 2,172 | 2,159 |
Gross Profit | 2,677 | 3,287 | 2,628 | 2,089 | 1,954 |
Selling, General & Admin | 612.61 | 608.54 | 739.98 | 627.83 | 599.41 |
Research & Development | 159.99 | 142.79 | 139.95 | 122.01 | 133.21 |
Other Operating Expenses | 61.64 | 53.92 | 42.36 | 44.92 | 47.06 |
Operating Expenses | 896.4 | 814.99 | 921.64 | 796.02 | 779.55 |
Operating Income | 1,781 | 2,472 | 1,706 | 1,293 | 1,174 |
Interest Expense | -7.34 | -5.12 | -3.65 | -2.41 | -3.09 |
Interest & Investment Income | 39.06 | 104.78 | 92.74 | 90.19 | 80.92 |
Currency Exchange Gain (Loss) | -0.03 | -0.04 | 0 | 0.01 | -0 |
Other Non Operating Income (Expenses) | -5.71 | -0.37 | -5.01 | -0.7 | -3.05 |
EBT Excluding Unusual Items | 1,807 | 2,571 | 1,790 | 1,380 | 1,249 |
Impairment of Goodwill | - | -45.99 | - | - | - |
Gain (Loss) on Sale of Assets | -2.77 | -7.33 | -1.04 | 13.55 | -0.3 |
Asset Writedown | - | -0.23 | -0.22 | -0.03 | -14.28 |
Other Unusual Items | 18.54 | 29.76 | 9.65 | 32.63 | 6.77 |
Pretax Income | 1,823 | 2,547 | 1,799 | 1,426 | 1,241 |
Income Tax Expense | 332.84 | 434.95 | 289.14 | 221.6 | 172.2 |
Earnings From Continuing Operations | 1,490 | 2,112 | 1,509 | 1,205 | 1,069 |
Minority Interest in Earnings | -399.04 | -563.1 | -399.57 | -323.76 | -308.8 |
Net Income | 1,091 | 1,549 | 1,110 | 880.92 | 760.01 |
Net Income to Common | 1,091 | 1,549 | 1,110 | 880.92 | 760.01 |
Net Income Growth | -29.59% | 39.58% | 25.99% | 15.91% | 18.94% |
Shares Outstanding (Basic) | 1,983 | 1,986 | 1,982 | 1,994 | 1,940 |
Shares Outstanding (Diluted) | 1,983 | 1,986 | 1,982 | 1,994 | 1,940 |
Shares Change (YoY) | -0.14% | 0.21% | -0.62% | 2.79% | 7.41% |
EPS (Basic) | 0.55 | 0.78 | 0.56 | 0.44 | 0.39 |
EPS (Diluted) | 0.55 | 0.78 | 0.56 | 0.44 | 0.39 |
EPS Growth | -29.49% | 39.29% | 26.78% | 12.77% | 10.73% |
Free Cash Flow | -266.78 | -247.63 | 1,316 | -228.02 | -151.35 |
Free Cash Flow Per Share | -0.14 | -0.13 | 0.66 | -0.11 | -0.08 |
Dividend Per Share | 0.200 | 0.100 | 0.125 | 0.042 | 0.069 |
Dividend Growth | 100.00% | -20.00% | 199.76% | -39.91% | - |
Gross Margin | 43.41% | 54.49% | 50.72% | 49.02% | 47.51% |
Operating Margin | 28.87% | 40.98% | 32.93% | 30.34% | 28.55% |
Profit Margin | 17.69% | 25.68% | 21.43% | 20.67% | 18.48% |
Free Cash Flow Margin | -4.32% | -4.11% | 25.40% | -5.35% | -3.68% |
EBITDA | 2,180 | 2,803 | 1,954 | 1,452 | 1,313 |
EBITDA Margin | 35.34% | 46.48% | 37.72% | 34.07% | 31.92% |
D&A For EBITDA | 398.93 | 331.52 | 248.17 | 158.74 | 138.65 |
EBIT | 1,781 | 2,472 | 1,706 | 1,293 | 1,174 |
EBIT Margin | 28.87% | 40.98% | 32.93% | 30.34% | 28.55% |
Effective Tax Rate | 18.26% | 17.08% | 16.08% | 15.54% | 13.88% |
Revenue as Reported | 6,168 | 6,032 | 5,180 | 4,261 | 4,112 |
Advertising Expenses | 0.42 | 1.89 | 1.63 | 5.26 | 6.35 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.